Medicines must be produced reliably for patients to benefit from scientific progress. German contract development and manufacturing organization IDT Biologika develops and manufactures medical products for pharmaceutical and biotechnology partners to honor its mission: “With passion, we bring pharmaceutical solutions to life.”

Part of South Korean vaccine and biotechnology company SK Bioscience, IDT Biologika is headquartered in Dessau-Rosslau/Saxony-Anhalt and has supported pharmaceutical and biotech companies for more than 100 years. It manufactures vaccines, biosimilars, sterile injectables, monoclonal antibodies, and gene and immune therapies, as well as proteins produced using cell cultures and microbes.

Japan’s advanced healthcare sector, active research environment and progress in new treatments have prompted IDT to pursue partnerships with drug developers in one of the world’s leading biopharmaceutical markets.

“Japanese companies are advancing biologics, vaccines, viral vectors, gene therapies and other complex modalities that align closely with our capabilities,” the company highlighted.

Participation in Interphex Tokyo and BioJapan 2026 provided valuable opportunities for direct discussions with prospective partners. IDT wants to understand their needs and develop relationships that endure from early development through commercial supply.

Through a single partner, customers gain access to the full value chain, from process and analytical development to technology transfer, manufacturing, sterile filling, packaging and quality control. Proprietary technologies and internally developed cell lines support technology transfer and efficient scale-up of production.

All production activities comply with good manufacturing practices and are supported by integrated supply chain solutions for both clinical and commercial programs.

“Partners rely on us for scientific expertise, transparent communication and dependable project delivery over many years,” IDT Biologika added.

The company emphasizes robust quality-control systems, regulatory compliance and collaborative project management. These practices meet Japanese pharmaceutical businesses’ expectations for quality, reliability and sustained cooperation.

IDT Biologika sees a practical role to play in German-Japanese life sciences cooperation by helping Japanese drug developers prepare therapies for clinical and commercial manufacturing. The company plans to strengthen its presence in Japan through trusted relationships and increased visibility, offering flexible European production tailored to the specific needs of global development programs.

“Our ambition is to support Japanese innovators from early development to commercialization, helping bring new therapies to patients worldwide,” the company pointed out.